Document text
Principal Investigator: paolo lusso
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2023
Award: $101,616
Funding agency: National Institute of Allergy and Infectious Diseases
Following the success of our HIV-1 vaccine platform based on co-formulated Env+Gag mRNA in order to produce non-infectious VLPs (Zhang et al., Nat. Med. 27:2234, 2021), in collaboration with Moderna, Inc., we have designed a similar vaccine platform for SARS-CoV-2. The major results obtained thus far include the following:
1. We synthesized different tail-modified SARS-CoV2 envelope spikes (S) in order to facilitate cognate Spike-Gag interaction and VLP formation with lentivirus core proteins. To promote the assembly of VLPs containing lentivirus (HIV-1 or SIV) core proteins, we have designed S proteins modified in their cytoplasmic tails (CT) by replacement of the natural tail with either the HIV-1 or SIV gp41 CT. A truncated form of the SIV tail (Sst) has been selected based on its ability to promote a more efficient surface membrane expression. Moderna Inc. has produced all the specific mRNAs according to our design.
2. In vitro, we tested the efficiency of production of VLPs with the modified spike proteins. The spike protein mRNAs were co-transfected into mammalian cells in all possible combinations with mRNAs encoding HIV-1 or SIV Gag or Gag-Pol. The extracellular VLPs were harvested and concentrated by ultracentrifugation on sucrose cushions. The produced VLPs have been extensively characterized both quantitatively and qualitatively using a wide array of physical and immunological assays, including virion capture by mAbs followed by ELISA for lentivirus core antigen quantification, Western blot and others.
3. In vivo, we tested the immunogenicity of our hybrid SARS-CoV-2-SIV VLP-forming vaccine in BALB/c mice. The animals were vaccinated with SSt+gag mRNA or Set alone at 0, 4 and 16 weeks. The VLP-forming vaccine (Sst+Gag) induced higher titers of Spike-binding and autologous neutralizing antibodies at all time points compared to SSt mRNA alone. Furthermore, mice immunized with SSt+gag mRNA developed neutralizing antibodies effective against different variants of concern.
These data demonstrate that the Gag/VLP mRNA platform can be successfully applied to vaccines against different agents for the prevention of infectious diseases of global relevance.
Our research on pathogenesis led to the identification of circulating anti-PF4 antibodies associated with disease severity in patients with COVID-19. The pathogenic mechanisms that trigger the most severe complications of COVID-19, which are often fatal, are still largely unknown. Severe COVID-19 is frequently associated with thrombosis and thrombocytopenia, which are reminiscent of the clinical presentation of two life-threatening syndromes: heparin-induced thrombocytopenia (HIT), which develops in patients treated with high doses of heparin after cardiac or orthopedic surgery, and vaccine-induced thrombosis with thrombocytopenia (VITT), which is a rare complication of adenovirus-vectored COVID-19 vaccines. The pathogenic mechanism of both the HIT and VITT syndromes involves the elicitation of autoantibodies that target partially cryptic epitopes in the a-chemokine platelet factor 4 (PF4 or CXCL4), which are fully revealed upon binding to heparin or other polyanionic molecules. Using a clinically validated immunoassay, we evaluated the presence of antibodies to PF4 in 100 hospitalized patients with COVID-19 with moderate or severe disease (WHO score, 4 to 10), 25 acute COVID-19 cases visiting the Emergency Department (ED) and 65 convalescent individuals. Anti-PF4 antibodies were detected in 95 of 100 (95.0%) hospitalized COVID-19 patients irrespective of prior heparin treatment, with a mean optical density value of 0.871 0.405 (range, 0.177-2.706). In contrast, patients hospitalized for severe acute respiratory disease unrelated to COVID-19 had markedly lower levels. In a high proportion of COVID-19 patients, all three isotypes tested (IgG, IgM and IgA) were simultaneously elevated. Higher antibody levels were detected in males than in females, and in African Americans and Hispanics than in White Caucasians. Anti-PF4 antibody levels were correlated with the maximum disease severity score and with significant reductions in circulating platelet counts during hospitalization. In individuals convalescent from COVID-19, the antibody levels returned to near-normal values. Sera from COVID-19 patients induced higher levels of platelet activation than sera from healthy blood donors, but the results were not correlated with the levels of anti-PF4 antibodies.
These results demonstrate that the vast majority of patients with severe COVID-19 develop anti-PF4 antibodies, which may play a role in the clinical complications of COVID-19, and have implications for the therapeutic management of the most severe cases.
Terms: <19S Gamma Globulin><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><7S Gamma Globulin><Acute><Ad vector><Adenoviral Vector><Adenovirus Vector><African American group><African American individual><African American people><African American population><African Americans><Animals><Antibodies><Antigenic Determinants><Antigens><Antiheparin Factor><Autoantibodies><Autologous><BALB C Mouse><BALB/c><Binding><Binding Determinants><Blood Platelet Count><Blood Platelet Factor IV><Blood Platelet Number><Blood Vessels><Blood donor><Blood platelet factor 4><COVID complications><COVID infected patient><COVID patient><COVID positive patient><COVID related complications><COVID-19><COVID-19 complications><COVID-19 infected patient><COVID-19 patient><COVID-19 positive patient><COVID-19 related complications><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 patient><COVID19 positive patient><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cardiac Surgery><Cardiac Surgery procedures><Cardiac Surgical Procedures><Caucasian><Caucasian Race><Caucasians><Caucasoid><Caucasoid Race><Chemokine (C-X-C motif) Ligand 4><Chemotactic Cytokines><Clinical><Clinical Treatment Moab><CoV emergence><CoV-2><CoV2><Collaborations><Communicable Diseases><Complication><Core Protein><Cytoplasmic Domain><Cytoplasmic Tail><Data><Development><Diffuse><Disease><Disorder><Dose><ED visit><ELISA><ER visit><Emergency care visit><Emergency department visit><Emergency hospital visit><Emergency room visit><Enzyme-Linked Immunosorbent Assay><Epitopes><Factor 4><Female><Glycoproteins><HIV-1><HIV-1 vaccine><HIV-I><HIV1><HIV1 vaccine><Harvest><Heart Surgical Procedures><Heparin><Heparin Neutralizing Protein><Heparinic Acid><Hispanic Populations><Hispanic group><Hispanic individual><Hispanic people><Hispanics><Homologous Chemotactic Cytokines><Hospital Admission><Hospitalization><Human Immunodeficiency Virus Type 1><Human immunodeficiency virus 1><Hybrids><IgA><IgG><IgM><Immune response><Immunize><Immunoassay><Immunoblotting><Immunoglobulin A><Immunoglobulin G><Immunoglobulin M><Immunological response><Immunology procedure><In Vitro><Inbred BALB C Mice><Individual><Infectious Disease Pathway><Infectious Diseases><Infectious Disorder><Intercrines><Lentivirinae><Lentivirus><Life><MOF syndrome><Mammalian Cell><Membrane><Messenger RNA><Mice><Mice Mammals><Molecular Interaction><Monoclonal Antibodies><Multiple Organ Dysfunction Syndrome><Multiple Organ Failure><Murine><Mus><Normal Range><Normal Values><Occidental><Optics><Orthopedic Surgery><PF4 Gene><Pathogenesis><Pathogenicity><Patients><Platelet Activation><Platelet Count><Platelet Count measurement><Platelet Factor 4><Platelet Number><Prevention><Production><Protein Subunits><Proteins><Recombinant Platelet Factor 4><Research><Respiratory Disease><Respiratory System Disease><Respiratory System Disorder><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 infected patient><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SCYB4><SIS cytokines><SIV><SIV envelope protein gp41><SIV gp40><SIV gp41><Saccharose><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Severity of illness><Simian Immunodeficiency Viruses><Small Inducible Cytokine B4><Small Inducible Cytokine Subfamily B, Member 4><Sucrose><Surface><Syndrome><Tail><Technology><Testing><Therapeutic><Thrombocytopenia><Thrombopenia><Thrombosis><Time><Ultracentrifugation><Vaccinated><Vaccination><Vaccines><Virion><Virus><Virus Assembly><Virus Particle><Virus-like particle><Western Blotting><Western Immunoblotting><Wuhan coronavirus><adeno vector><adenovector><autoimmune antibody><autoreactive antibody><chemoattractant cytokine><chemokine><complications due to COVID-19><corona virus disease 2019><corona virus disease 2019 vaccine><corona virus emergence><coronavirus disease 2019><coronavirus disease 2019 infected patient><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease infected patient><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease-19><coronavirus disease-19 patient><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus emergence><coronavirus infectious disease-19><coronavirus patient><density><design><designing><developmental><disease severity><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><enzyme linked immunoassay><experience><extracellular><gamma-Thromboglobulin><hCoV19><heart surgery><heparin-induced thrombocytopenia><host response><immune system response><immunogen><immunogenicity><immunologic assay><immunologic assay/test><immunoresponse><improved><in vivo><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><mAbs><mRNA><male><membrane structure><monoclonal Abs><multiorgan failure><multiple organ system failure><nCoV><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><neutralizing antibody><new CoV><new corona virus><new coronavirus><novel CoV><novel corona virus><novel coronavirus><optical><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><platelet factor IV><protein blotting><self reactive antibody><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><success><thrombotic disease><thrombotic disorder><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus><vaccine platform><variants of concern><vascular><viral assembly><virus-like nanoparticles><viruslike particle><white race>